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Abstract 24 
Many polycation-based gene delivery vectors show high transfection in vitro, but their 25 
cationic nature generally leads to significant toxicity and poor in vivo performance which 26 
significantly hampers their clinical applicability. Unlike conventional polycation-based 27 
systems, decationized polyplexes are based on hydrophilic and neutral polymers. They are 28 
obtained by a 3-step process: charge-driven condensation followed by disulfide crosslinking 29 
stabilization and finally polyplex decationization. They consist of a disulfide-crosslinked 30 
poly(hydroxypropyl methacrylamide) (pHPMA) core stably entrapping plasmid DNA (pDNA), 31 
surrounded by a shell of poly(ethylene glycol) (PEG). In the present paper the applicability 32 
of decationized polyplexes for systemic administration was evaluated. Cy5-labeled 33 
decationized polyplexes were evaluated for stability in plasma by fluorescence single 34 
particle tracking (fSPT), which technique showed stable size distribution for 48 h unlike its 35 
cationic counterpart. Upon incubation of the polymers used for the formation of polyplexes 36 
with HUVEC cells, MTT assay showed excellent cytocompatibility of the neutral polymers. 37 
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The safety was further demonstrated by a remarkable low teratogenicity and mortality 1 
activity of the polymers in a zebrafish assay, in great contrast with their cationic counterpart. 2 
Near infrared (NIR) dye-labeled polyplexes were evaluated for biodistribution and tumor 3 
accumulation by noninvasive optical imaging when administered systemically in tumor 4 
bearing mice. Decationized polyplexes exhibited an increased circulation time and higher 5 
tumor accumulation, when compared to their cationic precursors. Histology of tumors 6 
sections showed that decationized polyplexes induced reporter transgene expression in 7 
vivo. In conclusion, decationized polyplexes are a platform for safer polymeric vectors with 8 
improved biodistribution properties when systemically administered. 9 
 10 
KEYWORDS Gene delivery, polymer, nanoparticle, biocompatibility, biodistribution, EPR 11 
 12 
 13 
1. INTRODUCTION 14 
Gene therapy has generated great interest to be used as a therapeutic tool to solve unmet 15 
medical needs [1, 2] and relies on the development of safe and efficient vectors. Nonviral 16 
vectors, such as cationic polymers, lipids or peptides, have been investigated in depth 17 
because of their flexibility and easiness of preparation when compared to viral vectors [3-9].  18 
Polyplexes are normally formed by adding an excess of polycations to pDNA to yield 19 
positively charged and small-sized polyplexes which can, however, lead to significant toxicity 20 
in vivo [10, 11]. Toxicity of polycation-based vectors was especially evident for the “first-21 
generation” homopolymer systems. Upon intravenous administration, cationic polyplexes 22 
show great instability in vivo, since they interact with negatively charged blood components 23 
(e.g. proteins, erythrocytes), followed by the formation of aggregates, leading to severe in 24 
vivo toxicity (lung embolism and/or liver necrosis) and uncontrollable biodistribution and off-25 
targeting transfection [10-12]. Furthermore, cationic polymers/dendrimers might induce 26 
immunogenicity, complement activation and even blood coagulation [12-14]. 27 
Several strategies have been proposed and investigated to improve the in vivo behavior 28 
of polyplexes. Coating of polycation-based systems with PEG, effectively avoids formation 29 
of aggregates and reduces protein binding, resulting in improvements of the circulation 30 
kinetics and tumor accumulation in vivo [12, 15, 16]. Another strategy to improve polyplex 31 
stability consists of the incorporation of disulfide crosslinks into the polyplex core. Disulfide 32 
crosslinks stabilize the polyplex structure in the bloodstream, avoiding unwanted 33 
disassembly in circulation, but these bonds can be rapidly cleaved in the intracellular 34 
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reducing milieu [17-19]. In vivo, introduction of disulfide crosslinks, have demonstrated to 1 
improve circulation kinetics [20], as well as to improve tumor accumulation and transfection 2 
upon systemic administration [21]. However, further improvements on the blood circulation 3 
kinetics and biodistribution are of utmost importance to achieve the desired selective 4 
accumulation into target tissues. Even when shielded with PEG, the cationic groups of 5 
conventional polyplexes can also lead to unspecific cell binding in highly vascularized 6 
organs and, consequently, to poor in vivo biodistribution and insufficient blood circulation 7 
half-life [22, 23]. 8 
The major challenge for the clinical applicability of polymeric vectors is to achieve 9 
therapeutic efficacy with minimal toxicity and side effects upon systemic administration. 10 
Toxicity arising from polycations occurs not only on the systemic level but also at the cellular 11 
basis. Introduction of biodegradability into cationic polymers lead to the development of safer 12 
systems [5, 24]. However, during the development of new gene delivery polymer, toxicity is 13 
measured with cell viability assays in limited concentrations and exposure times, likely 14 
leading to underestimation of the toxicity problem. Toxicity is a complex process and 15 
requires deeper analysis at both acute and long term basis. When cationic polyplexes are 16 
taken up by cells, they will firstly compromise the cell membrane integrity [25-27]. 17 
Polycations can also disrupt the cell homeostasis by interaction with cellular polyanions (e.g. 18 
cell receptors, enzymes, mRNA or genomic DNA) [28]. Polycations can change the genomic 19 
expression profile [29-31] and induce activation of oncogenes or even apoptosis [26, 32]. 20 
Such consequences are directly related to the polycationic nature of synthetic vectors and 21 
have a substantial impact on the safety of such systems. Accordingly, neutral polymer based 22 
systems are a logical step to obtain not only improved blood circulation kinetics and 23 
biodistribution but also to accomplish the necessary safety requirements.  24 
In previous work the development of decationized polyplexes was reported [33, 34]. 25 
These polyplexes constitute of a core of disulfide-crosslinked pHPMA, surrounded by a PEG 26 
shell. Complexation with DNA to form polyplexes occurs by the transient presence of cationic 27 
charge in the core of the polyplexes. After structure stabilization by interchain disulfide 28 
crosslinking, the cationic groups are removed by hydrolysis, leading to a disulfide 29 
crosslinked polyplex based on a neutral polymer. As a result, entrapment of pDNA is 30 
exclusively based on disulfide crosslinks, providing an intracellularly triggered release 31 
mechanism. This means that pDNA release from decationized polyplexes occurs exclusively 32 
in a reducing environment, such as the intracellular milieu [17-19]. Importantly, the 33 
decationized polyplexes, in contrast to their cationic precursor, showed a low degree of 34 
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nonspecific uptake, which is thought to be an important advantage for improved blood 1 
circulation and higher target tissue accumulation exploiting the enhanced permeation and 2 
retention (EPR) effect [35].  3 
In this study, we evaluated the stability, safety and in vivo biodistribution as well as the 4 
ability of decationized polyplexes for tumor targeting applications. The stability in biological 5 
fluids was evaluated by fSPT [36], as well as the safety by the teratogenicity and mortality 6 
potential in zebrafish embryo assay in parallel with cytotoxicity tests in vitro [37], and 7 
biodistribution and tumor accumulation in a A431 tumor-bearing mice by noninvasive optical 8 
imaging based on the combination micro-computed tomography (μCT) and fluorescence 9 
molecular tomography (FMT) [38]. Finally, transgene expression was also assessed by 10 
histological analysis of tumor cryosections.  11 
 12 
 13 
2. MATERIALS AND METHODS 14 
2.1. Materials 15 
N-hydroxysuccinimide (NHS) ester functionalized dyes Cyanine5 NHS ester (Cy5-NHS) 16 
and Cyanine7 NHS ester (Cy7-NHS) were obtained from Lumiprobe (Hannover, Germany). 17 
Carbonyldiimidazole (CDI) activation of N,N’-dimethylaminoethanol (DMAE) was performed 18 
as previously described to yield DMAE-CI [39]. N-[2-(2-pyridyldithio)]ethyl methacrylamide 19 
(PDTEMA) was synthesized as previously described [33]. N-(3-20 
aminopropyl)methacrylamide hydrochloride (APMA) was obtained from Polysciences 21 
(Eppelheim, Germany). The synthesis and characterization of (mPEG)2-ABCPA (4,4′-22 
azobis(4-cyanovaleric acid)) macroinitiator was done as previously described [40, 41]. 2,4,6-23 
Trinitrobenzene sulfonic acid (TNBSA) was obtained from ThermoScientific (Etten-Leur,The 24 
Netherlands). pCMV_EGFP plasmid, encoding for enhanced green fluorescent protein 25 
(EGFP) with human cytomegalovirus promoter (CMV), was amplified with competent E. coli 26 
DH5α and purified with NucleoBond® (Macherey-Nagel, Bioke, Leiden, The Netherlands). 27 
pCMV_EGFP construction was described by van Gaal et al. [42]. MTT Cell Proliferation Kit 28 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was purchased from Roche 29 
(Basel, Switzerland). Zebrafish medium was prepared in-house [37]. All other chemicals and 30 
reagents were obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). The following 31 
buffer systems were used: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) for 32 
buffering at pH 6.8-8.2; 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]propane-1-33 
sulfonic acid (TAPS) for buffering at pH pH 7.7-9.1. 34 
 35 
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2.2. Polymer synthesis 1 
2.2.1 Synthesis of p(HPMA-co-PDTEMA-co-APMA)-b-PEG 2 
Free radical polymerization using 5 kDa PEG bi-functionalized azo macroinitiator (PEG)2-3 
ABCPA was performed to synthesize p(HPMA-co-PDTEMA-co-APMA)-b-PEG (Scheme 1). 4 
The polymers were synthesized using a monomer to initiator ratio (M/I) of 220 (mol/mol). 5 
The feed ratio HPMA/PDTEMA/APMA was 1/0.2/0.01 (mol/mol/mol). The polymerization 6 
was carried at 70 °C for 24 h in DMSO under an N2 atmosphere, using 5 μmol macroinitiator 7 
and a monomer concentration of 0.4 M. After polymerization, the obtained product was 8 
precipitated in diethyl ether and collected by centrifugation. After removing ether under 9 
vaccum, the product was dissolved in 2.5 mM NH4OAc pH 5 buffer and dialyzed for 2 days 10 
at 4 °C (MWCO 6000−8000 Da) against the same buffer. Finally, the product was collected 11 
by freeze-drying.  12 
Unreacted PEG was removed by precipitation in cold EtOH (5 mg/mL of solids) followed 13 
by centrifugation and filtration over a 0.2 µm filter. The product, solubilized in EtOH, was 14 
collected after EtOH evaporation, dissolution in water and freeze-drying. 15 
 16 
2.2.2. Synthesis of p(HPMA-DMAE-co-PDTEMA-co-Cy5/Cy7)-b-PEG 17 
Firstly, a solution of p(HPMA-co-PDTEMA-co-APMA)-b-PEG·TFA) (Mw = 44.1 kDa; 10 18 
mg, 46.75 nmol NH2/mg polymer, 1 eq.) was prepared in 100 µL DMSO. Next, the polymer 19 
solution was slowly added to a 0.01 M Cy7-NHS or Cy5-NHS solution in 93.5 µL DMSO 20 
(935 nmol, 2 eq), containing 2.3 µmol (5 eq.) triethylamine (Scheme 2). The reaction was 21 
performed for 36 h (in the dark) under stirring and N2 atmosphere. 22 
To determine the coupling efficiency, the crude product was diluted to a final polymer 23 
concentration of 1 mg/mL in DMF containing 10 mM LiCl and analyzed by GPC equipped 24 
with a UV detector set at 646 nm for Cy5 and 700 nm for Cy7 detection. The coupling 25 
efficiency was determined by analyzing the area under the curve (AUC) of the polymer and 26 
unreacted dye peaks. AUC was determined using GraphPad Prism 5 (GraphPad Software 27 
Inc., La Jolla, California, USA). 28 
A 1 M DMAE-CI solution in DMSO (451.5 µmol), corresponding to a 10-fold excess to 29 
HPMA reactive groups of the polymer, was added to the reaction mixture. The reaction was 30 
performed at room temperature for 24h, in the dark and N2 atmosphere to yield p(HPMA-31 
DMAE-co-PDTEMA-co-Cy5/Cy7)-b-PEG (Scheme 2). After completion of the reaction, 1 M 32 
acetic acid was added to adjust the pH 5. Removal of free dye was performed by dialysis 33 
against a mixture of EtOH/water 10 mM NH4Ac pH 5 (50/50) for 2 days. The polymer was 34 
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collected by freeze-drying after buffer exchange to 5 mM NH4Ac pH 5 and desalting using 1 
PD-10 (GE Healthcare Life Sciences) columns following the supplier’s protocol. 2 
 3 
2.2.3. Preparation of p(HPMA-co-PDTEMA)-b-PEG 4 
To prepare p(HPMA-co-PDTEMA)-b-PEG (pHP-PEG), 5 mg of p(HPMA-DMAE-co-5 
PDTEMA)-b-PEG (pHDP-PEG) was dissolved in 2.5 mL 10 mM HEPES 10 mM TAPS pH 6 
8.5 buffer and hydrolyzed for 6 h at 37 ºC. After hydrolysis the polymer was purified with a 7 
PD-10 column following the supplier’s protocol and collected by freeze-drying.  8 
 9 
2.3. 1H NMR characterization of the polymers 10 
The composition of the polymers was determined by 1H NMR analysis performed with a 11 
400 MHz Agilent 400-MR NMR spectrometer (Agilent Tecnologies, Santa Clara, USA) in 12 
DMSO-d6. The ratio HPMA/PDTEMA was determined by comparison of the integrals at δ 13 
4.6 ppm (bs, CH2CHCH3O, HPMA) and the integral at δ8.5 ppm (bs, pyridyl group proton, 14 
PDTEMA) (∫δ4.6/∫δ8.5). The integral ratios between δ4.2 ppm (bs, OCH2CH2), HPMA-DMAE) 15 
and δ4.6 ppm (bs, CH2CHCH3O, HPMA-DMAE) was used to verify reaction between DMAE-16 
CI and hydroxyl groups in the polymer from HPMA.  17 
The number average molecular weight (Mn) of the polymers was determined according 18 
to equation (1). 19 
 20 
Mn = (∫δ4.6 × M(HPMA/HPMA-DMAE + ∫δ8.5× MPDTEMA)/( ∫δ3.5/448) + 5000 (g/mol) (1) 21 
 22 
where, ∫δ3.5, ∫δ4.6 and ∫δ8.5 are the integrals at 3.5, 4.6, and 8.5 ppm, respectively. MHPMA, 23 
MHPMA-DMAE and MPDTEMA are the molar masses of HPMA, HPMA-DMAE and PDTEMA, 24 
respectively. The number of protons for the 5000 Da PEG block, at ∫δ3.5, was set at 448.  25 
 26 
2.4. UV spectroscopy characterization of the polymers 27 
UV spectroscopy was performed on Shimadzu UV-2450 UV/VIS spectrophotometer (‘s-28 
Hertogenbosch, The Netherlands) to quantify the molarity of thiol reactive pyridyl disulfide 29 
(PDS) groups per weight of polymer. Polymer stock solutions of 1 mg/mL were prepared in 30 
20 mM HEPES pH 7.4 containing 50 mM tris(2-carboxyethyl)phosphine (TCEP). After 31 
incubation for 1 h at 37 ºC the UV absorbance at 343 nm was measured to determine the 32 
released 2-mercaptopyridine (2-MP) [43]. Quantification was performed using a calibration 33 
curve with 2-MP standards. 34 
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To quantify the molarity of dye Cy7 or Cy5 per weight of polymer, polymer stocks of 1 1 
mg/mL in DMSO were prepared and the UV absorbance was measured at 646 nm for pHDP-2 
Cy5-PEG or 750 nm for pHDP-Cy7-PEG. The quantification was done using a calibration 3 
curve of dye standards in DMSO. 4 
 5 
2.5. TNBSA assay 6 
In order to determine the molarity of free primary amines in p(HPMA-co-PDTEMA-co-7 
APMA)-b-PEG, the TNBSA assay was performed [44]. Polymer solutions were prepared at 8 
1 mg/mL in 0.1M sodium bicarbonate buffer (pH 8.5) using glycine standards. The amine 9 
content was determined by detecting the absorbance at 420 nm. 10 
 11 
2.6. Gel permeation chromatography (GPC) characterization of the polymers 12 
GPC analysis of the polymers was performed using a Waters System (Waters Associates 13 
Inc., Milford, MA) with refractive index (RI) and UV detector using two serial Plgel 5 μm 14 
MIXED-D columns (Polymer Laboratories) and DMF containing 10 mM LiCl as eluent. The 15 
flow rate was 1 mL/min (30 min run time) and the temperature was 60 °C. The average 16 
molecular weight (Mn), weight average molecular weight (Mw) and polydispersity (PDI, 17 
Mw/Mn) was determined by calibration with a series PEG calibration standards of different 18 
molecular weights and with narrow molecular weight distribution. 19 
 20 
2.7. Preparation of decationized polyplexes 21 
The preparation of Cy5/Cy7-labeled decationized polyplexes was adapted from the 22 
method previously described (Scheme 3) [33]. In order to prepare a high concentrated 23 
polyplex dispersion 400 μg/mL pDNA, 80 µL of aqueous solution of pHDP-PEG was mixed 24 
with 160 µL pDNA (pCMV_EGFP) (600 μg/mL) in 10 mM HEPES 10 mM TAPS pH 8.5 buffer 25 
containing 5% glucose. The amount of polymer added to the pDNA solution corresponded 26 
to N/P=4 (N, molarity of positively charged amines from polymer; P, molarity of negatively 27 
charged phosphates from pDNA)). Subsequently, the formed polyplexes were crosslinked 28 
by addition of dithiothreitol (DTT) corresponding with a half molar equivalent to PDS groups 29 
of the polymer, in order to induce self-crosslinking of the polyplexes [45] for 1 h at pH 8.5 at 30 
room temperature.  31 
To prepare decationized pHP-PEG polyplexes, the cationic DMAE side groups were 32 
removed by hydrolysis by incubation of the polyplex dispersions at 37 °C in 10 mM HEPES 33 
10 mM TAPS, pH 8.5 for 6 h [33]. Next, the pH of the dispersion was adjusted to pH 7.4. For 34 
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cationic pHDP-PEG polyplexes the pH was adjusted to pH 7.4 immediately after completion 1 
of the crosslinking step. When polyplexes needed to be stored for long periods, the pH of 2 
the dispersions was adjusted to pH 5 and the dispersions were stored at 0-5 ºC, with the pH 3 
being readjusted to pH 7.4 immediately before use. Comparative studies were always 4 
performed by dividing the same batch of polyplexes into pHDP-PEG cationic and pHP-PEG 5 
decationized polyplexes. Given the fact that the side products from cross-linking and 6 
decationization (2-mercaptopyridine and DMAE) have a high cellular tolerance [33, 45, 46], 7 
the polyplexes were directly used without purification procedures.  8 
 9 
 10 
2.8. Particle size and zeta potential determination 11 
The size of the polyplexes was measured with DLS on an ALV CGS-3 system (Malvern 12 
Instruments, Malvern, UK) equipped with a JDS Uniphase 22 mW He-Ne laser operating at 13 
632.8 nm, an optical fiber-based detector, a digital LV/LSE-5003 correlator with temperature 14 
controller set at 25 °C or 37 °C. Measurements were performed in HBS (20 mM HEPES, 15 
150 mM NaCl, pH 7.4) at a pDNA concentration of 40 µg/mL. 16 
Size distribution and polydispersity of the polyplexes were also determined by 17 
nanoparticle tracking analysis (NTA) measurements on a NanoSight LM10SH (NanoSight, 18 
Amesbury, United Kingdom), equipped with a sample chamber with a 532-nm laser. 19 
Polyplexes were diluted in phosphate buffered saline (PBS) to a concentration of 0.1 µg/mL 20 
pDNA and measured for 160 s with manual shutter and gain adjustments. The captured 21 
videos were analyzed by the NTA 2.0 image analysis software (NanoSight, Amesbury, UK). 22 
The detection threshold was set to 2 and the minimum track length to 10. The mode and 23 
mean size and SD values were obtained by the NTA software. 24 
The zeta potential (ζ) of the polyplexes was measured using a Malvern Zetasizer Nano-25 
Z (Malvern Instruments, Malvern, UK) with universal ZEN 1002 ‘dip’ cells and DTS (Nano) 26 
software (version 4.20) at 25 °C. Zeta potential measurements were performed in 20 mM 27 
HEPES pH 7.4 at a pDNA concentration of 10 µg/mL. 28 
 29 
2.9. Stability using fluorescence single particle tracking (fSPT) 30 
fSPT was performed to measure the stability of the cationic pHDP-PEG polyplexes and 31 
decationized pHP-PEG polyplexes in full human plasma. fSPT is a fluorescence microscopy 32 
technique that uses wide-field and a fast and sensitive CCD camera to record movies of 33 
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diffusing particles in biofluids. These movies are analyzed using in-house developed 1 
software, to obtain size distributions as previously described [36]. 2 
fSPT measurements were performed as follows: a volume of 5 µL of sample of Cy5-3 
labeled polyplex dispersion in HEPES buffer (20 mM pH 7.4) or in fresh plasma (10 µg/mL 4 
final pDNA concentration) was placed between a microscope slide and cover glass with 5 
double-sided adhesive sticker, following incubation for different time points at 37 °C. Both 6 
the objective and the sample were kept at 37 °C during the measurements using an objective 7 
heater (Bioptechs, Butler, USA) and a sample heater (Linkam, Surrey, U.K.). Videos were 8 
recorded with the NIS Elements software (Nikon) driving the EMCCD camera (Cascade 9 
II:512, Roper Scientific, AZ, USA) and a TE2000 inverted microscope equipped with a 100_ 10 
NA1.4 oil immersion lens (Nikon). To convert SPT diffusion measurements to size 11 
distributions, the viscosity of human plasma at 37 °C was set to 1.35 cP [36]. Human plasma 12 
was obtained from a healthy donor at UMC Utrecht. Blood was collected in EDTA tubes 13 
which were cooled on ice and subsequently centrifuged at 4 ºC, 2000 ×g for 10 min and 14 
plasma was isolated and stored at -80 ºC. 15 
 16 
2.10. Cell Culture  17 
HUVEC (human umbilical vein endothelial) cells were obtained from human umbilical 18 
cords and cultured in Endopan 3 (E3) medium (Pan Biotech, Germany), supplemented with 19 
1% penicillin/streptomycin. A431 epidermoid carcinoma cells (ATCC) were cultured in 20 
Dulbecco's modified Eagle's Medium (DMEM; Gibco, Invitrogen, Germany), supplemented 21 
with 10% fetal bovine serum (FBS) (Invitrogen, Germany) and with 1% 22 
penicillin/streptomycin. Cell lines were kept at 37 °C and 5% CO2, in a humidified 23 
atmosphere. 24 
 25 
2.11. MTT assay  26 
The cell viability upon incubation with decationized pHP-PEG and cationic pHDP-PEG 27 
polymers was evaluated via MTT assay, which measures the cellular metabolic activity of 28 
the cells. HUVECs were seeded into 96-well plates: 12,000 cells were seeded per well for 29 
24 h test and 1,950 cells per well were seeded for the 72 h test. After 24 h, the medium was 30 
refreshed and 30 µL of polymer samples in PBS was added to each well corresponding to 31 
a final concentration of 0.01-3 mg/mL also containing 12% FBS. After 24 h or 72 h, the MTT 32 
assay (Roche) was performed according to the manufacturer’s protocol. First, cells were 33 
washed with 200 µL PBS and 100 µL of cell culture medium was added per well. Next, MTT 34 
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labeling reagent was added to a final concentration of 0.5 mg/mL. After 4 h at 37 ºC and 5% 1 
CO2, the medium was discarded and 100 μL of DMSO was added per well to dissolve the 2 
formed formazan crystals. The plate was protected from light and formazan crystals were 3 
dissolved overnight at room temperature. The supernatants (100 µL) were then transferred 4 
into another 96-well plate and the absorbance was measured at 570 nm using reference 5 
wavelength of 690 nm. 6 
 7 
2.12. In vivo toxicity using the zebrafish embryo assay 8 
The in vivo toxicity of decationized pHP-PEG and cationic pHDP-PEG polymers was 9 
evaluated using the zebrafish (Danio rerio) embryo assay based on the method previously 10 
described in detail by Rizzo et al. [37]. In short, fertilized eggs were transferred into round-11 
bottom 96-well plates (16-cell stadium, 1 egg per well). Polymers were diluted in fish medium 12 
corresponding to polymer concentrations ranging from 0.1 to 3 mg/mL. As positive control, 13 
branched polyethylenimine (b-PEI) 25 kDa was tested at 0.1 mg/mL. The development and 14 
survival of the zebrafish embryos was evaluated for 72 h every 24 h post-fertilization using 15 
a Leica DMI 6000B inverted microscope. 16 
 17 
2.13. Animal experiments 18 
CD-1 nude female mice were fed chlorophyll-free food pellets and water ad libitum. Mice 19 
were housed in ventilated cages and clinically controlled rooms and atmosphere. CD-1 nude 20 
mice were inoculated with A431 tumor cells (4×106 cells/100 μL) subcutaneously into the 21 
left flank 15 days before experiment, which lead to the development of A431 tumor 22 
xenografts with an approximate size of 6-7 mm in width. 23 
Decationized pHP-PEG polyplexes (group 1, n=3 and cationic pHDP-PEG polyplexes 24 
(group 2, n=3) were tested for their in vivo biodistribution and tumor accumulation. Polyplex 25 
dispersions labeled with Cy7 were injected (80 µL, 32 µg pDNA, 2.5 nmol Cy7) into mice via 26 
tail vein under anesthesia. Immediately after sample injection, µCT (Tomoscope DUO; CT 27 
Imaging, Erlangen, Germany) and 3D FMT imaging (FMT2500; PerkinElmer), were 28 
performed essentially as previously described [38]. Briefly, mice were placed in a multi-29 
modal imaging cassette under anesthesia (2% of isoflurane) to be firstly scanned in a µCT. 30 
Images with an isotropic voxel size of 35 µm were reconstructed using a modified Feldkamp 31 
algorithm with a smooth kernel. Immediately after µCT procedure, the animals were placed 32 
into the FMT docking station under 2% isoflurane anesthesia. The excitation wavelength 33 
channel was set to 750 nm. Whole body images of the mice were captured using FRI to 34 
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allow the definition of the region of interest (ROI) and 3D scans were performed. µCT and 1 
3D FMT images were collected 15 min, 4 h, 24 h and 48 h post-injection.  2 
The obtained μCT and FMT scans were fused. Based on the μCT data, liver, kidneys, 3 
lungs, heart, bladder and tumor were segmented, using an Imalytics Research Workstation 4 
software (Philips Technologie GmbH Innovative Technologies, Aachen, Germany). FMT 5 
reconstructed signals were overlapped onto respective organ-segmented μCT images, and 6 
the amount accumulated Cy7 in these organs was quantified. The percentage injected dose 7 
(% ID) was calculated based on the quantification obtained for each segmented organ and 8 
normalized to the organ volume. In parallel to the imaging protocol, blood and urine samples 9 
were also collected at relevant time 2 min, 15 min, 1 h and 4 h for blood and 1 h, 4 h and 24 10 
h for urine collection. 11 
 12 
2.15. Ex vivo analysis 13 
Mice were injected intravenously with rhodamine-labeled lectin (Vector Laboratories, 14 
LTD, UK), for staining of blood vessels, 15 min before sacrifice and 48h after sample 15 
injection. Tumors, liver, spleen, heart, lungs, uterus, intestines, muscle and skin were 16 
collected, weighted and analyzed by 2D Fluorescence reflectance imaging (FRI) at the FMT 17 
at the 750 nm channel. Tumors were preserved in Tissue-Tek® O.C.TTM compound (Sakura, 18 
The Netherlands) at -80 °C for immunohistochemistry. 19 
 20 
2.16. Histological analysis 21 
Histological staining was performed to analyze the Cy7-labeled polyplex accumulation in 22 
tumors. Simultaneously, EGFP expression in the tissue was evaluated in order to determine 23 
the degree of transfection for both decationized pHP-PEG and cationic pHDP-PEG 24 
polyplexes. Frozen 8 µm sections were prepared, where blood vessels were previously 25 
stained by rhodamine-lectin perfusion. Sections were mounted using Mowiol and 26 
fluorescence microscopy imaging was performed using an Axio Imager M2 microscope and 27 
a high-resolution AxioCam MRm Rev.3 camera, at magnification 40×. Images of 3 28 
independent sections per animal were further post-processed using AxioVision Rel 4.8 29 
software (Carl Zeiss Microimaging GmbH, Göttingen, Germany) and analyzed for Cy7 signal 30 
(polyplex accumulation) and EGFP signal (transfection efficiency). 31 
 32 
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2.17. Statistical analysis  1 
Statistical analysis for comparison between means were performed with the software 2 
GraphPad Prism 5 (GraphPad Software Inc., La Jolla, California, USA) and a two-tailed 3 
paired Student's t-test was used, where p<0.05 was considered to represent statistical 4 
significance. 5 
 6 
 7 
3. RESULTS AND DISCUSSION  8 
3.1. Synthesis of fluorescently labeled p(HPMA-DMAE-co-PDTEMA)-b-PEG 9 
The stability evaluation by fSPT and the in vivo evaluation by 3D-FMT of decationized 10 
polyplexes required the synthesis of Cy5- and Cy7-labeled pHDP-PEG. which was 11 
performed in 3 steps (Scheme 1). First, p(HPMA-co-PDTEMA-co-APMA)-b-PEG was 12 
synthesized via free-radical polymerization of HPMA, PDTEMA and APMA using mPEG)2-13 
ABCPA as a PEG5000 bi-functionalized azo macronitiator [40] (Scheme 1). The yield of 14 
polymerization was close to 75%. The results of the analysis of the polymer by 1H NMR (Fig. 15 
1), GPC and TNBSA assay are given in Table 1. The different monomers were incorporated 16 
in the polymer close to the feed ratio. The Mn calculated by 1H NMR (44.0 kDa) is in good 17 
agreement with GPC (34.4 kDa, PDI=1.6). The incorporation of PDTEMA was confirmed by 18 
UV, and a value of 821±43 nmol per mg of polymer was found, which is very close to the 19 
value calculated by NMR (863 nmol per mg of polymer; thus around 40 units of PDTEMA 20 
were present per polymer chain). The TNBSA assay showed that approximately 2 units 21 
APMA per polymer chain were present. 22 
 23 
Scheme 1. Synthesis of p(HPMA-co-PDTEMA-co-APMA)-b-PEG, by free-radical polymerization of 24 
HPMA, PDTEMA and APMA using ((mPEG5000)2-ABCPA) macroinitiator. 25 
 26 
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Table 1. p(HPMA-co-PDTEMA-co-APMA)-b-PEG characteristics as determined by GPC, 1H NMR, 1 
UV spectroscopy and TNBSA assay. 2 
GPC NMR NMR, TNBSA UV 
Mn (kDa) PDI Mn (kDa) 
Feed 
HPMA-DMAE/PDTEMA/APMA 
Polymer 
HPMA-DMAE/PDTEMA/APMA nmolPDS/mgpolymer 
34.4 1.6 44.0 1/0.20/0.01 1/0.19/0.01 821.0±43.3 
 3 
 4 
NHS-functionalized dyes were conjugated to p(HPMA-co-PDTEMA-co-APMA)-b-PEG by 5 
reaction with the primary amines of APMA for 36 h using a 2 molar excess of reactive dyes 6 
(Scheme 2). After reaction, the crude product was analyzed with GPC, and the coupling 7 
efficiency was determined by GPC analysis of the AUC of the polymer and unreacted dye 8 
peaks (detection at 646 nm (Cy5 coupling) or 700 nm (Cy7 coupling)). The obtained 9 
chromatograms revealed that the AUC for each peak was close to 50% for both reactions, 10 
demonstrating that the amine groups of the polymers were quantitatively modified with dye 11 
molecules. In Fig. 2a shows the GPC chromatogram of the crude product from Cy7 coupling 12 
reaction. In the third step, the crude product (e.g. p(HPMA-co-PDTEMA-co-(Cy5/Cy7)-b-13 
PEG) was reacted with DMAE-CI (Scheme 2) to yield the cationic polymer p(HPMA-DMAE-14 
co-PDTEMA-co-(Cy5/Cy7)-b-PEG. After purification of the polymer by extensive dialysis, 1H 15 
NMR (Fig. 1) showed that the integral ratio between peaks at δ4.2 ppm (bs, OCH2CH2), 16 
HPMA-DMAE) and δ4.6 ppm (bs, CH2CHCH3O, HPMA-DMAE) was close to 2, confirming 17 
a quantitative reaction of the OH groups of HPMA with DMAE-CI. GPC analysis of the final 18 
purified products showed complete removal of the unreacted dyes for both Cy5- and Cy7-19 
labeled polymer (e.g. Fig. 2b for Cy7-labeled polymer). The modification of HPMA groups 20 
with the cationic DMAE groups after dye coupling was chosen over the direct polymerization 21 
of HPMA-DMAE monomer [33, 34] because of the incompatibility of the carbonate ester 22 
bond in HPMA-DMAE with primary amines. 23 
 24 
 25 
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 1 
Scheme 2. Synthesis of p(HPMA-DMAE-co-PDTEMA-co-Cy7)-b-PEG, by sequential coupling of 2 
Cy7-NHS and DMAE-CI to p(HPMA-co-PDTEMA-co-APMA)-b-PEG. 3 
 4 
 5 
Fig. 1. 1NMR spectra of p(HPMA-co-PDTEMA-co-APMA) and p(HPMA-DMAE-co-PDTEMA-co-Cy7)-6 
b-PEG in DMSO. 7 
 8 
 9 
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 1 
 2 
Fig. 2. GPC chromatograms (a) UV detection at 700 nm of the crude product from coupling of 3 
Cy7-NHS to p(HPMA-co-PDTEMA-co-APMA)-b-PEG, using a 2 molar equivalent excess of Cy7-NHS 4 
to primary amines in the polymer. (b) Refractive index signal (RI) and UV signal at 700 nm of the final 5 
purified p(HPMA-DMAE-co-PDTEMA-co-Cy7)-b-PEG polymer. 6 
 7 
3.2. Preparation of fluorescently labeled decationized pHP-PEG polyplexes 8 
Polyplexes of pHP-PEG were formed through the 3-step process [33, 34] (Scheme 3). 9 
The preparation of Cy5 or Cy 7-labeled decationized polyplexes started with the 10 
complexation of the cationic block copolymer p(HPMA-DMAE-co-PDTEMA-co-Cy5/Cy7)-b-11 
PEG (pHDP-PEG) with pDNA via electrostatic interactions. The interchain disulfide 12 
crosslinking of the polyplexes was performed via thiol-disulfide exchange reaction by 13 
addition of DTT corresponding to a 50% molar equivalent of the PDS groups of the polymer, 14 
to induce self-crosslinking of the polyplexes [45], yielding cationic pHDP-PEG polyplexes. 15 
To obtain decationized polyplexes from cationic precursors, decationization was performed 16 
by removal of the DMAE cationic side groups linked via carbonate ester bond to the HPMA 17 
backbone at pH 8.5 for 6.5 h. This process yields p(HPMA-co-PDTEMA-co-Cy5/Cy7)-b-PEG 18 
(pHP-PEG) decationized polyplexes. The structural stabilization and pDNA entrapment was 19 
solely dependent on the interchain disulfide crosslinks in the pHPMA-DMAE core. 20 
 21 
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 1 
Scheme 3. Route for the preparation of interchain disulfide-crosslinked decationized polyplexes, 2 
through a 3-step process: 1. charge-driven condensation with nuclei acids; 2. stabilization through 3 
disulfide crosslinking; 3. decationization of cationic pHDP-PEG polyplexes, resulting in decationized 4 
pHP-PEG polyplexes (adapted from [33]). 5 
 6 
An overview of the biophysical properties of both the decationized pHP-PEG and cationic 7 
pHDP-PEG polyplexes by DLS and zeta potential measurements is shown in Table 2. 8 
Polyplexes were prepared by complexing the polymer with pDNA at an optimal N/P=4 9 
regarding their biophysical and in vitro transfection properties [33]. Firstly, pHDP-PEG 10 
formed nanosized particles with a diameter of 140±5 nm and a positive zeta potential of 11 
+11±3. After decationization, pHP-PEG polyplexes had a size of 142±8 nm and a slightly 12 
negative zeta potential of -4±2 mV. The decrease in zeta potential, from cationic to 13 
decationized arises from to the loss of the cationic DMAE groups from the pHDP and from 14 
the entrapped pDNA in the core [33]. The loss of electrostatic interactions between the 15 
polymer and pDNA potentially leads to some hydration and thus slight swelling of the 16 
polyplex core, however by using a zero-length crosslinking agent such as DTT, this effect is 17 
limited. Size is a particularly critical property for the biodistribution of nanoparticles [47], 18 
however, here this variable is ruled out by evaluation polyplexes of very similar size. 19 
Both decationized pHP-PEG and cationic pHDP-PEG polyplexes were complementarily 20 
analyzed by NTA, a technique that allows the simultaneous analysis of individual particles 21 
in a suspension and gives information of the true size distribution (Fig. 3) [48]. Similarly to 22 
DLS, decationized polyplexes and cationic polyplexes showed comparable average sizes 23 
(around 145-150 nm). Importantly, the size distribution measured by NTA displayed similar 24 
distribution profiles: for both particles, when prepared at high concentration for in vivo 25 
applications (400 µg/mL), around 90% of the polyplexes had a size below 210 nm. Size and 26 
17 
 
charge measurements demonstrate that introduction of cyanine fluorophores and 1 
preparation of polyplexes at high concentration did not affect significantly the polyplexes 2 
properties [33, 34]. 3 
 4 
Table 2. Particle z-average diameter (Z-avg) and polydispersity index (PDI) determined by DLS, and 5 
particle charge (ζ Pot) determined by zeta potential measurements, of decationized pHP-PEG and 6 
cationic pHDP-PEG polyplexes. Results are expressed as mean±SD (n=3). 7 
Polyplexes DLS Zetasizer 
Z-ave (nm) PDI ζ Pot (mV) 
pHP-PEG 142±8 0.20±0.01 -4±2 
pHDP-PEG 140±5 0.19±0.01 11±3 
 8 
 9 
 10 
 11 
Fig. 3. Decationized pHP-PEG and cationic pHDP-PEG polyplexes size distribution determined by 12 
NTA in PBS at 25 ºC. 13 
 14 
3.3. Stability of decationized pHP-PEG polyplexes in human plasma 15 
The stability of cationic pHDP-PEG and decationized pHP-PEG Cy5-labeled was 16 
evaluated by incubation at 37 ºC in human plasma. The size distribution of the polyplexes 17 
in plasma was determined by fSPT and compared to the distributions obtained when 18 
polyplexes were diluted in HEPES buffer pH 7.4 (Fig. 4). The method is based on single 19 
particle tracking analysis of fluorescent particles which allows the determination of precise 20 
size distributions in media with intrinsic light scattering such as undiluted biological fluids 21 
[36]. The fSPT technique is especially important to gain information on the possible 22 
aggregation of nanoparticles. When Cy5-labeled polyplexes, both cationic and decationized, 23 
were measured in HEPES buffer by fSPT, comparable size distributions to the ones 24 
obtained by DLS and NTA were observed. The distribution was relatively narrow, with a 25 
peak around 200 nm. When the cationic pHDP-PEG  polyplexes were incubated in human 26 
plasma for 1 h, a clear change in the distribution profile was observed and a higher average 27 
size (~300 nm) as well as polyplexes with >400 nm in diameter were clearly detected. Upon 28 
incubation for 48 h, the average size (560 nm) and the population of polyplexes with 29 
18 
 
diameter >400 nm was increased. The instability detected for crosslinked cationic 1 
polyplexes likely occurs is due to insufficient shielding of the positive charge of the 2 
polyplexes by PEG and consequent interaction of polyplexes with negatively charged 3 
proteins from plasma. Indeed, table 2 shows that the cationic  pHDP-PEG  polyplexes have 4 
a positive zeta-potential. Importantly, when pHP-PEG decationized polyplexes were 5 
incubated with human plasma for 1 h, only a slight change of the size distribution was 6 
observed, and the peak of the distribution remained unchanged. Consequently, crosslinked 7 
decationized polyplexes retained their integrity in biological fluids, and did not show 8 
aggregation (mediated e.g. by plasma proteins). For example, almost no polyplexes with a 9 
diameter of >400 nm were detected which is in great contrast with the cationic polyplexes. 10 
In line with this, also after incubation the polyplexes for 48 h the size distribution only 11 
changed slightly, without any aggregation detected. A slight increase in size after 48 h 12 
probably occurs due to protein adsorption to the polyplexes as a consequence of loss of 13 
PEG density due to continuous hydrolysis of the ester bond linking PEG chains with HPMA-14 
co-PDTEMA block. PEG is essential to stabilize nanoparticles, avoid aggregation and 15 
protein adsorption in blood. This is quite evident for cationic particles [12, 15, 16], but 16 
essential for anionic particles as well [49, 50]. 17 
The stability assessment is especially important for systemic administration of polyplexes. 18 
Firstly in terms of safety, cationic polymer based systems, when administered intravenously 19 
lead to the formation of aggregates by interactions with negatively charged blood 20 
components. These aggregates can be retained in the lungs causing embolism and 21 
consequent death [12]. Other severe consequences comprise liver necrosis and as 22 
uncontrollable distribution and expression [10]. The assessment of the stability is also 23 
important to ensure the success of these systems when applied intravenously. In order to 24 
target tumors, polyplexes should also possess prolonged circulation and maintain a stable 25 
size in the order of few hundreds of nanometers to reach and extravasate in the tissue leaky 26 
tumor vasculature, via EPR effect [51-53]. Decationization of polyplexes complemented by 27 
the shielding properties of PEG, significantly improves the stability of polyplexes when 28 
compared to their cationic polyplexes and therefore increasing the chances to target tumors 29 
via EPR. 30 
 31 
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 1 
Fig. 4. The size distribution of cationic pHDP-PEG and decationized pHP-PEG polyplexes as 2 
determined by fSPT after incubation in 90% (v/v) human plasma at 37 ºC for 1 h and 48 h. Size 3 
distribution was also determined in 20 mM HEPES pH 7.4. 4 
 5 
3.4. In vitro and in vivo toxicity assessment 6 
To assess the toxicity of the decationized pHP-PEG and cationic pHDP-PEG, the 7 
polymers were evaluated in vitro with HUVEC cells via MTT assay in an acute (24 h) and a 8 
long term toxicity test (Fig. 5a) and in vivo with a zebrafish embryo model (Figs. 5b and 5c) 9 
with different polymer concentrations (0.1 to 3 mg/mL). The cationic polymer b-PEI, a 10 
commonly used transfection agent, was used as a positive control for toxicity [37]. 11 
The in vitro toxicity was tested in HUVEC cells due their high sensitivity towards 12 
transfection agents [54]. The MTT test revealed that decationized pHP-PEG had no effect 13 
on the cell viability, in any of the concentrations tested, when incubated with the cells for 24 14 
h. Only a slight decrease on the cell viability was found in case incubation was prolonged 15 
for 72 h. The in vitro evaluation of the cationic pHDP-PEG polymer showed that the polymer 16 
lead to decrease in cell viability with increasing concentrations, to a level of 70% cell viability 17 
for 3 mg/mL when tested for acute toxicity. For long term toxicity test (72 h incubation) the 18 
20 
 
cytotoxic effects were even more pronounced and at 1 mg/mL already lead to decrease in 1 
cell viability to 20%. In the case of b-PEI extreme toxicity was observed, at the lowest 2 
concentration tested (0.1 mg/mL) b-PEI induced complete cell death in both acute and long 3 
term in vitro toxicity test. 4 
The zebrafish eggs were incubated with increasing polymer concentrations, and 5 
teratogenic effect and the mortality potential on the different zebrafish embryonic stages 6 
were monitored microscopically for a period of 72 h. The neutral polymer pHP-PEG showed 7 
no effect on the fish viability for any of the concentrations tested. Developmental defects 8 
and delayed hatching were observed only for the highest concentration tested (3 mg/mL). 9 
For the cationic polymer pHDP-PEG a significant decrease on zebrafish viability was 10 
observed at 3 mg/mL, resulting in 100% fish death at 72 h. Mortality was also detected at a 11 
very early stage of the development (1 out of 6) together with a slower heartbeat in the 12 
surviving ones. Furthermore, the cationic pHDP-PEG also interfered significantly in the 13 
embryonic development of the fishes. A decrease in the pigmentation was observed from a 14 
concentration of 0.3 mg/mL onwards, no hatching was observed at 48 h for 1 mg/mL and at 15 
3 mg/mL all fish had a decreased heartbeat. In line with the in vitro test, b-PEI was again 16 
responsible for extreme toxicity, by inducing complete fish death at 0.1 mg/mL even at early 17 
stages of development. 18 
Evident toxicity was induced by the biodegradable cationic pHDP-PEG polymer, 19 
particularly observed on long term (observed in HUVEC cells and zebrafish). Toxicity is 20 
obviously less than b-PEI, but by using a wide range of concentrations and exposure times 21 
we evidence that biodegradability is not sufficient for a completely safe gene delivery 22 
system. We demonstrate not only effects on cell and organism viability but also on the 23 
teratogenicity potential observed in zebrafish embryos at lower concentrations. In great 24 
contrast, a practically innocuous profile of the decationized pHP-PEG was observed in short 25 
and long term in vitro and and in the zebrafish assay. This contrast between decationized 26 
and cationic polymers proves the importance of developing gene delivery systems based on 27 
neutral polymers in order to build safe vectors. 28 
 29 
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Fig. 5. Safety evaluation of decationized polyplexes (a) HUVEC cell relative viability relative upon 3 
exposure for 24 h or 72 h to decationized pHP-PEG, cationic pHDP-PEG and b-PEI from 0.1 mg/mL 4 
to 3 mg/mL. Results are expressed as mean±SD (n=4). (b) Representative images of zebrafish 5 
embryo development upon exposure to decationized pHP-PEG and to cationic pHDP-PEG at 6 
concentrations ranging from 0.1-3 mg/mL. * significant mortality, ** significant developmental defects 7 
(i.e. decreased pigmentation, delayed hatching ratio and slower heartbeat). (c) zebrafish survival 8 
upon exposure to decationized pHP-PEG and cationic pHDP-PEG polymers in comparison with b-PEI 9 
(* 100% mortality; n=6). hpf (hours post-fertilization). 10 
 11 
3.5. In vivo biodistribution and tumor accumulation 12 
Cy7-labeled pHP-PEG decationized and pHDP-PEG cationic polyplexes were 13 
intravenously injected into mice bearing subcutaneous A431 tumors, and their biodistribution 14 
and tumor accumulation were noninvasively monitored using 3D µCT-FMT. Hybrid µCT-15 
FMT method allows the effective in vivo visualization of near-infrared (NIR) dye labeled 16 
nanomedicines, and the (semi-) quantification of their accumulation in tumors and healthy 17 
organs. By fusing and reconstructing 3D FMT data with µCT images, and by performing 18 
absorption pre-scans, a more accurate assignment of fluorescence signals to deep internal 19 
organs tissues can be performed [38, 55, 56]. Compared to the 2D FRI, 3D µCT-FMT is not 20 
limited to superficial visualization, animal sacrificing is not required.  21 
22 
 
In parallel with 3D µCT-FMT images, blood circulation kinetics was determined by 2D FRI 1 
signals of blood and urine collected at different time points p.i (Fig. 6). Quantification of 2 
polyplex signals in blood showed that there was a very rapid decrease of the %ID for both 3 
cationic and decationized polyplexes which typical for polyplex systems when administered 4 
intravenously [15, 16, 22, 57, 58] (Fig. 6a). Importantly, a significant higher blood circulation 5 
time was observed for decationized pHP-PEG polyplexes. Decationized polyplexes showed 6 
a higher signal in blood at all time points when compared to cationic pHDP-PEG. The 7 
elimination rate via kidneys was determined by detecting 2D FRI signals from urine (Fig. 8 
6b). High Cy7 %ID was detected in urine 15 min p.i. for both groups, followed by a rapid 9 
decrease 4 h p.i. Most likely, this was due to a rapid glomerular filtration of low Mw polymer 10 
fraction that is not built in the polyplexes. This fraction of polymers is the same for both 11 
cationic and decationized polyplexes, as confirmed by the similar signals found for both 12 
polyplexes. 13 
 14 
 15 
Fig. 6. 2D FRI quantification as %ID (per 100 µl) of decationized pHP-PEG and cationic pHDP-PEG 16 
Cy7-labeled polyplexes signals in (a) blood and (b) urine at different time points p.i. Results are 17 
expressed as mean±SD (n=3). *p<0.01 (t test). 18 
 19 
As shown in Fig. 7, using µCT imaging, tumors, liver, heart, lungs, kidneys and bladder 20 
were manually segmented, to assign the NIR fluorescence signals from the polyplexes at 21 
different times points, as previously described [38]. Next, the accumulation of pHP-PEG 22 
decationized and pHDP-PEG cationic polyplexes in tumors and different organs was 23 
23 
 
quantified. Quantification in tumors showed higher normalized %ID detected in tumors for 1 
decationized polyplexes when compared to their cationic counterpart 48 p.i. Also, for 2 
decationized polyplexes increasing accumulation in tumors was observed with the highest 3 
accumulation point at 48 h p.i. In contrast, for cationic polyplexes an accumulation plateau 4 
was rapidly reached (within 15 min), which have been previously observed for other cationic 5 
systems [22].  6 
Both polyplexes showed a high accumulation in healthy organs, mainly in liver and 7 
kidneys 15 min p.i. However, in the case of decationized polyplexes there was a rapid signal 8 
decrease at 4 h p.i. resulting in an apparent lower accumulation of decationized polyplexes 9 
in liver and kidneys, when compared to cationic polyplexes. Most likely decationized 10 
polyplexes were able to maintain a population of polyplexes in the circulation or rapidly 11 
accumulated in the different organs, but due to their improved ability to maintain small and 12 
stable size in biological fluids (Fig. 4) together with their low unspecific uptake properties 13 
[33, 34], polyplexes can reenter the blood circulation and accumulate in tumor tissues. This 14 
behavior been previously described for other nanoparticulate systems [59, 60].  15 
The major organ of polyplex accumulation of polyplexes was the liver, which contains 16 
Kupffer cells as part of the mononuclear phagocyte system (MPS) which are responsible for 17 
phagocytic activity and rapid clearance of nanoparticles in vivo [60-62]. Liver accumulation 18 
is very critical for PEGylated polymer-DNA complexes [15, 22, 57]. The ability of 19 
decationized polyplexes to escape from liver and remain stable in circulation more efficiently 20 
determines their higher circulation in vivo. As hypothesized PEG is not able to completely 21 
shield cationic particles, leading to unspecific uptake or opsonization, which in turn leads to 22 
decreased circulation time when compared to the decationized polyplexes.  23 
Significant NIR signal was noticed in the bladder 15 min p.i. for both groups with similar 24 
degrees and with a rapid drop of signal 4 h p.i. The signals profile are in line with the results 25 
determined by 2D FRI in urine and as quantified, the initial elimination into the bladder 26 
corresponds to 15-20 total %ID. 27 
Accumulation in kidneys was also pronounced, with a tendency of higher accumulation 28 
of cationic polyplexes. Kidney accumulation has been previously found for polymeric vectors 29 
[57, 63, 64]. Kidney retention can be particularly critical for polycation-based systems. The 30 
nanoparticles within the kidney will have pass through the glomerulus which is in close 31 
contact with glomerular basement membrane (GBM), a 300- to 350-nm-thick basal lamina 32 
rich in negatively charged proteoglycans, to which particles of around 100 nm can access 33 
24 
 
[65]. Ultimately, particle retention in the GBM is driven by the surface charge, leading to 1 
cationic particles to be retained [66].  2 
It is also important to point out that no significant lung deposition was observed for both 3 
systems. Lung capillaries are among the smallest blood vessels and sieving might occur in 4 
case aggregates are formed [60], which is normally associated with acute toxicity or off-5 
targeting transfection [10, 12]. Our results demonstrate that both polyplexes do not induce 6 
acute aggregation in vivo in line with the results shown in Fig.4. 7 
 8 
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Fig. 7. Noninvasive in vivo 3D CT-FMT imaging of the biodistribution and tumor accumulation of 1 
decationized pHP-PEG and cationic pHDP-PEG Cy7-labeled polyplexes. (a) Principle of 3D CT-FMT 2 
imaging: anatomical information obtained using µCT is used to assign the Cy7 signals coming from 3 
polyplexes to a specific organ or tissue of interest. The images were obtained at 15 min, 4 h, 24 h 4 
and 48 h p.i. and show Cy7 localization mainly in liver (red) and kidney (orange). Tumor accumulation 5 
was more prominent for decationized polyplexes. (b) Quantification of the tumor accumulation and 6 
biodistribution of Cy7-labeled decationized pHP-PEG and cationic pHDP-PEG polyplexes in tumors, 7 
liver, lungs, kidney, bladder and heart, expressed as %ID per 100 mm3 tissue. Results are presented 8 
as mean±SD (n=3).  9 
 10 
3.6. Ex vivo for probe accumulation and in vivo transfection 11 
After the 3D µCT-FMT procedure at 48 p.i., mice were sacrificed and tumors, lungs, 12 
spleen, kidneys, heart skin, intestines and muscle were analyzed using 2D FRI (Figs. 8a 13 
and b). The NIR signals from tumors and several physiologically relevant healthy organs 14 
(liver, spleen, lungs and kidneys) were quantified and compared for both Cy7-labeled 15 
decationized pHP-PEG and cationic pHDP-PEG polyplexes. 2D FRI quantification 16 
determined ex vivo supports and further validates the results of the 3D µCT-FMT analysis. 17 
In the case of 2D FRI measurements, a significantly higher accumulation in the tumors was 18 
observed for decationized polyplexes. As determined by 3D µCT-FMT, it was also found 3 19 
times higher accumulation for decationized polyplexes. The tendency of a lower 20 
accumulation in healthy organs was also observed for decationized polyplexes with 2D FRI. 21 
Similar accumulation in liver was observed for both polyplexes 48 p.i., but in the case of 22 
spleen and kidneys higher accumulation was observed for cationic polyplexes. The spleen, 23 
together with liver constitutes the MPS. In the spleen nanoparticles are sieved and 24 
subsequently taken up by macrophages or splenocytes [60, 61]. The apparent lower 25 
retention of decationized polyplexes in the spleen further demonstrates the advantages of 26 
decationized polyplexes.  27 
Cryosections of tumors collected 48 p.i. were analyzed using fluorescence microscopy, 28 
to validate the in vivo and ex vivo Cy7-labeled polyplex accumulation results (Figs. 8c and 29 
d). By quantifying the Cy7 signals on tumor sections of both groups, 2 times higher signal 30 
was observed for decationized polyplexes with statistically significance. Microscopy was 31 
also used to determine the in vivo tumor transfection potential of both decationized pHP-32 
PEG and cationic pHDP-PEG polyplexes containing EGFP encoding pDNA (Figs. 8c and 33 
d).The EGFP signal, which allows to infer on the transfection ability of polyplexes, was 34 
similar for both systems, even though significant differences were found in NIR tumor 35 
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accumulation. Transfection requires polyplexes’ (extensive) uptake by the target cells. The 1 
lower transfection ability of decationized polyplexes is therefore likely attributed to its low 2 
degree of unspecific uptake. We also showed that uptake can be triggered by introduction 3 
of a targeting ligand at the surface of decationized polyplexes [33, 34]. Furthermore, 4 
introduction of targeting ligands is important to accelerate the rate of cellular uptake of 5 
polyplexes and prevent premature reduction of disulfide crosslinks before cell entry due to 6 
the presence of secreted and cell membrane thiols [67]. Cationic polyplexes, in contrast, are 7 
known to be taken up extensively by electrostatic interaction with cell membrane anionic 8 
components [3, 68, 69]. The transfection ability of cationic pHDP-PEG polyplexes is in line 9 
with previous findings of pHPMA-DMAE to induce in vivo transfection in tumors [70].  10 
It should be noticed that the ability of cationic polyplexes to transfect cells more efficiently 11 
has counterproductive effects because it also leads to an increased probability of off-12 
targeting expression, especially when high accumulation is observed in liver, spleen and 13 
kidneys. Unwanted transfection in healthy organs has been previously observed particularly 14 
in liver and lungs [16, 22, 71]. In recent years, several strategies have been developed to 15 
introduce target transfection with encouraging results [58, 63, 64, 72]. Decationized 16 
polyplexes can potentiate further specific transfection in tumors specially when a targeting 17 
ligand is introduced [34]. Furthermore, due to its low toxic and low teratogenic potential, 18 
decationized polyplexes are less limited to dose and repeated administration restrictions, 19 
resulting in a promising and attractive system for further optimization strategies and testing. 20 
Future studies have to be focused on deeper evaluation of transfection ability of optimized 21 
formulations of decationized polyplexes. Optimization for a better in vivo performance can 22 
be done by using targeted systems or by optimizing the polymer structure, for example by 23 
determining the best PEG block molecular weight and density [73, 74] or by introduction of 24 
hydrophobic groups in the core of polyplexes groups into polyplexes [75].In a next step, 25 
therapeutic genes should be used to determine the therapeutic potential of decationized 26 
polyplexes. 27 
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Fig. 8. Ex vivo analysis. (a) Representative ex vivo 2D FRI assessment of the tumor accumulation 3 
and biodistribution of decationized pHP-PEG and cationic pHDP-PEG Cy7-labeled polyplexes at 48 4 
h p.i. (b) Quantification of polyplex accumulation in tumors and healthy organs. Results are expressed 5 
as mean±SD (n=3). (c-d) Fluorescence microscopy imaging (c) and quantification (d) of decationized 6 
pHP-PEG and cationic pHDP-PEG Cy7-labeled polyplexes (blue) accumulating in tumors at 48 h p.i. 7 
and inducing EGFP expression (green). Blood vessels are labeled using rhodamine-lectin (red). 8 
Results are expressed as mean±SD (n=3). *p<0.05 (t test). 9 
 10 
 11 
4. CONCLUSIONS 12 
Decationized polyplexes, unlike conventional polycationic polymeric gene delivery systems, 13 
are based on neutral polymers. In the present study, we demonstrate that the neutral 14 
polymer pHP-PEG when tested for toxicity in vitro with HUVEC cells showed a very good 15 
cytocompatibility in both acute and long term toxicity test. Furthermore, an in vivo zebrafish 16 
toxicity assay revealed that pHP-PEG did not induce fish mortality and, importantly, showed 17 
a much lower teratogenicity potential when compared with its cationic counterpart. This 18 
28 
 
apparent safe polymer formed polyplexes with a high stability in biological fluids, as 1 
determined by fSPT, which validated its applicability in vivo applicability for systemic 2 
administration. Using noninvasive optical imaging (3D µCT-FMT) and complementary ex 3 
vivo analysis we demonstrated that by removing the cationic groups of polyplexes, we 4 
obtained a system with higher tumor accumulation, most likely due to their longer blood 5 
circulation and apparent decreased accumulation in healthy organs. Ex vivo analysis 6 
validated the optical imaging results and histology in tumor crysections and showed that 7 
decationized polyplexes induced transgene expression in vivo. 8 
The described strategy for preparing decationized polyplexes and the results reported are 9 
an important contribution to take into consideration to develop safer and more efficient 10 
nonviral gene delivery systems. 11 
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